- Alcon innovations featured in approximately 180 abstracts
across cataract, glaucoma, refractive, visualization and ocular
health1
- New data demonstrates comparable range of vision and
intermediate visual acuity between Clareon monofocal IOL and TECNIS
Eyhance* monofocal IOL2
- Alcon advances next-generation workflow connectivity,
integrating ARGOS Biometer with Image Guidance and newly available
NGENUITY 1.53-8
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will once again have the largest
surgical ophthalmic presence at the American Society of Cataract
and Refractive Surgery (ASCRS) 2023 Annual Meeting, taking place
May 5-8 in San Diego. The company is proud to have the benefits of
its innovations featured in more studies than ever in its history.1
Alcon will showcase product updates that drive efficiencies for
ophthalmologists and staff, and host events with surgeons sharing
their real-world experiences. Alcon ASCRS event information and
registration is available at MyAlconatASCRS.com.
“The pace of innovation happening across eye care is
extraordinary, and as the industry leader, we are excited to be
leading the charge at ASCRS 2023,” said Sergio Duplan, President,
North America at Alcon. “As a testament to our commitment to
groundbreaking research and innovation, we’re excited to have a
significant presence at ASCRS that underscores how our products are
changing the lives of patients and surgeons alike.”
Clinical studies continue to demonstrate benefits of Clareon®
Collection of intraocular lenses (IOLs). A study from
Micheletti et. al. evaluates a head-to-head comparison of distance
and intermediate vision of Clareon monofocal IOL and TECNIS
Eyhance* monofocal IOL. The study concludes that Clareon monofocal
IOLs provided excellent distance and comparable intermediate vision
that was non-inferior to TECNIS Eyhance monofocal IOLs.2 Dr. J.
Morgan Micheletti will be presenting his full findings on May 6
from 11:09-11:14 a.m., during the “Cataract IOLs-Monofocal/Extended
Depth of Focus II session,” Upper Level, Room 4.2
Additional data on Alcon IOLs will be presented,
including:9-10
- Prospective Analysis of PanOptix® Satisfaction and Higher Order
Aberrations in Patients with Prior Myopic Laser Vision Correction,
Presented by Dr. Brett H. Mueller II (May 6, 9:05-9:10 a.m.)
- Evaluation of Refractive Stability and Binocular Visual Acuity
in a New Monofocal Hydrophobic Acrylic Intraocular Lens, Presented
by Dr. Clayton Blehm (May 6, 1:45-1:50)
ARGOS® Biometer is now connected to NGENUITY® 1.5, enabling
surgeons to conduct 3D digital image-guided cataract surgery,
increasing workflow efficiency and precision.3-8 ARGOS biometry
measurements and images can now be imported to NGENUITY 1.5,
enabling cataract surgeons to precisely overlay incision location,
capsulorhexis, IOL centration and toric alignment. Now available in
the U.S., the open-platform NGENUITY 1.5 offers superior
visualization** and includes usability, color, contrast and
magnification enhancements.4,† NGENUITY 1.5 will be featured at
Alcon Booth #2111.
Data will be presented at ASCRS demonstrating how surgeons
benefit from using ARGOS and NGENUITY in their practices:11-13
- Comparison Trial Evaluating Axial Lengths and Predicted
Spherical Equivalents of Three Biometers, Presented by Dr. Sam
Multack (Electronic Poster)
- Comparing Refractive Outcomes of a Swept-Source Optical
Coherence Tomography Biometer and an Optical Low Coherence
Reflectometry Biometer, Presented by Dr. Clayton G. Blehm (May 6,
3:35-3:40 p.m.)
- Development of Phototoxic Maculopathy as a Function of Coaxial
Illumination Intensity in Diabetic Patients at the Time of Cataract
Surgery, Presented by Lopa S Shah (May 6, 4:20-4:25 p.m.)
New data on the Hydrus® Microstent reinforce significant
intraocular pressure (IOP) reduction in glaucoma patients with
higher baseline IOP compared to those who receive cataract surgery
alone.14 Dr. Cathleen McCabe will present these new findings
from a randomized, controlled clinical trial on May 6 from
2:27-2:32 p.m. These new findings are derived from the HORIZON
5-year trial results, which had previously demonstrated that the
Hydrus Microstent offers long-term glaucoma medication reduction
and reduction of IOP.14 Surgeons can learn more about the Hydrus
Microstent and Alcon pharmaceutical glaucoma products at booth
#2111.
Additional data supporting Alcon innovation in cataract glaucoma
patients include:15-16
- Clinical Outcomes of a Non-Diffractive Extended Depth-of-Focus
IOL in Eyes with Glaucoma, Presented by Dr. Tanner J. Ferguson (May
6, 8:00-8:05 a.m.)
- Visual Performance of a Trifocal IOL in Subjects with
Open-Angle Glaucoma Undergoing Concurrent Minimally Invasive
Glaucoma Surgery, Presented by Dr. Steven D. Vold (May 6, 1:50-1:55
p.m.)
Evidence supports that phacoemulsification in cataract
surgery with CENTURION® Vision System with ACTIVE SENTRY® allows
surgeons to operate at a more physiological IOP with
excellent anterior chamber stability and surgical efficiency.17
A study by Vaishali Vasavada showed that rise of IOP to baseline
following occlusion break response was faster with ACTIVE SENTRY
handpiece as compared to traditional handpiece when using the
CENTURION Vision System.17 The full study will be presented on
Sunday, May 7 at 1:45 pm.
Additional data on CENTURION with ACTIVE SENTRY
include:18-20
- Improved Surgical Times Using Active Sentry™ Hand Piece on the
Centurion™ Cataract System, a Randomized Controlled Trial,
Presented by Julio Echegoyen, MD, ABO (On-Demand Electronic Poster,
May 5, 8:05-8:10 p.m.)
- Surge and Capsule Dynamics during Phacoemulsification using an
Adjustable Compliance Mechanical Eye Model, Presented by Dr. Jaime
Zacharias (May 7, 4:45-4:50 p.m.)
- Evaluation of Early Changes of the Anterior Vitreous Interface
after Cataract Surgery, Using Low-Pressure Settings Determined by
OCT, Presented by Hugo A. Scarfone, MD; Emilia Carolina C.
Rodriguez, MD (May 6, 8:05-8:10 a.m.)
Additional educational opportunities and experiences for
surgeons will be available at the Alcon booth #2111. For
information on Alcon events and news at ASCRS, please visit
MyAlconatASCRS.com.
About Clareon® IOLs and Delivery
Systems
The family of Clareon® intraocular lenses (IOLs) includes the
Clareon® Aspheric Hydrophobic Acrylic and Clareon® Aspheric Toric
IOLs, the Clareon® PanOptix® Trifocal Hydrophobic IOL, Clareon
PanOptix® Toric, Clareon Vivity® Extended Vision Hydrophobic
Posterior Chamber IOL and Clareon® Vivity® Toric IOLs. Each of
these IOLs is indicated for visual correction of aphakia in adult
patients following cataract surgery. In addition, the Clareon®
Toric IOLs are indicated to correct pre-existing corneal
astigmatism at the time of cataract surgery. The Clareon® PanOptix®
lens mitigates the effects of presbyopia by providing improved
intermediate and near visual acuity while maintaining comparable
distance visual acuity with a reduced need for eyeglasses, compared
to a monofocal IOL. The Clareon® Vivity® lens mitigates the effects
of presbyopia by providing an extended depth of focus. Compared to
an aspheric monofocal IOL, the lens provides improved intermediate
and near visual acuity while maintaining comparable distance visual
acuity. All of these IOLs are intended for placement in the
capsular bag. Careful preoperative evaluation and sound clinical
judgment should be used by the surgeon to decide the risk/benefit
ratio before implanting any IOL in a patient with any of the
conditions described in the Directions for Use that accompany each
IOL. Prior to surgery, physicians should provide prospective
patients with a copy of the Patient Information Brochure available
from Alcon, informing them of possible risks and benefits
associated with these IOLs. Reference the Directions for Use
labelling for each IOL for a complete listing of indications,
warnings and precautions.
About ARGOS® Biometer with Image
Guidance
ARGOS® is a non-invasive, non-contact biometer based on
Swept-Source Optical Coherence Tomography (SS-OCT). The device is
intended to acquire ocular measurements as well as perform
calculations to determine the appropriate intraocular lens (IOL)
power and type for implantation during intraocular lens placement.
Please refer to the ARGOS® User Manual for a complete description
of proper use and maintenance, optical and technical
specifications, as well as a complete list of warnings and
precautions.
About NGENUITY® 3D Visualization
System
The NGENUITY® 3D Visualization System consists of a 3D
stereoscopic, high-definition digital video camera and workstation
to provide magnified stereoscopic images of objects during
micro-surgery. It acts as an adjunct to the surgical microscope
during surgery displaying real-time images or images from
recordings. Please refer to the User Manual for a complete list of
appropriate uses, warnings and precautions.
About Hydrus® Microstent
Roughly the size of an eyelash, the Hydrus® Microstent is a
next-generation MIGS device designed to reduce eye pressure by
reestablishing flow through Schlemm's canal, the eye's natural
outflow pathway. When placed in the canal during minimally invasive
microsurgery, the device restores the flow of fluid in the eye,
using a Tri-Modal® mechanism of action: the Hydrus® Microstent
dilates and scaffolds Schlemm's canal to augment outflow of aqueous
humor from the anterior chamber. It maintains an opening through
the trabecular meshwork from the anterior chamber into Schlemm's
canal. Its length spans approximately 90 degrees of the canal to
provide consistent access to multiple fluid collector channels in
the eye. Approved by the FDA in August 2018 for use in conjunction
with cataract surgery, the Hydrus® Microstent is one of the most
rigorously researched and thoroughly studied MIGS devices.
About CENTURION® Vision System with
ACTIVE SENTRY®
The CENTURION® Vision System with ACTIVE SENTRY® is indicated
for emulsification, separation, irrigation, and aspiration of
cataracts, residual cortical material and lens epithelial cells,
vitreous aspiration and cutting associated with anterior
vitrectomy, bipolar coagulation, and intraocular lens injection.
Appropriate use of CENTURION® Vision System parameters and
accessories is important for successful procedures. Please refer to
the CENTURION® Operator’s Manual for a complete description of
proper use and maintenance, as well as a complete list of
contraindications, warnings and precautions.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 25,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
* Trademarks are the property of their respective owners. **
Compared to analog microscopes, including the Leica Proveo 8 and
Zeiss OPMI LUMERA® 700 scopes. † Specified performance was achieved
at maximum system magnification with an aperture setting of 30%
open and viewing distance of 1.2 meters.
References
- Alcon Data on File.
- Micheletti JM, Duncan N, Hall B. Head-to-Head Comparison of
Intermediate Vision of Two Monofocal Intraocular Lenses. Presented
at the American Society of Cataract and Refractive Surgery (ASCRS)
Annual Meeting; May 5-8, 2023; San Diego, CA, USA.
- NGENUITY® 1.5 3D Visualization System User Manual.
- Berquet F, Henry A, Barbe C, et al. Comparing heads-up versus
binocular microscope visualization systems in anterior and
posterior segment surgeries: a retrospective study.
Ophthalmologica. 2020;243(5):347-354.
- Alcon Data on File.
- Mouro-Coelho N, Nascimento J, Henriques J, Medeiros MD.
Three-dimensional display systems in ophthalmic surgery – a review.
European Ophthalmic Review. 2019;13(1):31-36.
- Tamaoki A, Kojima T, Hasegawa A, et al. Clinical evaluation of
a new swept-source optical coherence biometer that uses individual
refractive indices to measure axial length in cataract patients.
Ophthalmic Res. 2019;19:1-13.
- Shammas HJ, Ortiz S, Shammas MC, et al. Biometry measurements
using a new large-coherence-length swept-source optical coherence
tomographer. J Cataract Refract Surg. 2016;42:50-61.
- Mueller BH, Saenz B, Parkhurst GD, Welburn KR. Prospective
Analysis of Panoptix Satisfaction and Higher Order Aberrations in
Patients with Prior Myopic Laser Vision Correction. Presented at
the American Society of Cataract and Refractive Surgery (ASCRS)
Annual Meeting; May 5-8, 2023; San Diego, CA, USA.
- Blehm Clayton G. Evaluation of Refractive Stability and
Binocular Visual Acuity in a New Monofocal Hydrophobic Acrylic
Intraocular Lens. Presented at the American Society of Cataract and
Refractive Surgery (ASCRS) Annual Meeting; May 5-8, 2023; San
Diego, CA, USA.
- Multack Sam. Comparison Trial Evaluating Axial Lengths and
Predicted Spherical Equivalents of Three Biometers. Presented at
the American Society of Cataract and Refractive Surgery (ASCRS)
Annual Meeting; May 5-8, 2023; San Diego, CA, USA.
- Blehm Clayton G. Comparing Refractive Outcomes of a
Swept-Source Optical Coherence Tomography Biometer and an Optical
Low Coherence Reflectometry Biometer. Presented at the American
Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting;
May 5-8, 2023; San Diego, CA, USA.
- Lopa SS, Rosenberg E. Development of Phototoxic Maculopathy as
a Function of Coaxial Illumination Intensity in Diabetic Patients
at the Time of Cataract Surgery. Presented at the American Society
of Cataract and Refractive Surgery (ASCRS) Annual Meeting; May 5-8,
2023; San Diego, CA, USA.
- McCabe Cathleen M. Increase in High Level IOP Reduction with a
Schlemm’s Canal Microstent: Outcomes from a Randomized, Controlled
Clinical Trial. Presented at the American Society of Cataract and
Refractive Surgery (ASCRS) Annual Meeting; May 5-8, 2023; San
Diego, CA, USA.
- Ferguson TJ, Wilson CW, Shafer BM, Berdahl JP, et al. Clinical
Outcomes of a Non-Diffractive Extended Depth-of-Focus IOL in Eyes
with Glaucoma. Presented at the American Society of Cataract and
Refractive Surgery (ASCRS) Annual Meeting; May 5-8, 2023; San
Diego, CA, USA.
- Vold SD, McFarland MR. Visual Performance of a Trifocal IOL in
Subjects with Open-Angle Glaucoma Undergoing Concurrent Minimally
Invasive Glaucoma Surgery. Presented at the American Society of
Cataract and Refractive Surgery (ASCRS) Annual Meeting; May 5-8,
2023; San Diego, CA, USA.
- Vasavada V, et. al. Comparison of Intraoperative Performance,
Intraocular Pressure and Postoperative Outcomes during Cataract
Surgery with Three Fluidic Systems. Presented at the American
Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting;
May 5-8, 2023; San Diego, CA, USA.
- Echegoyen Julio. Improved Surgical Times Utilizing Fluidic
Analysis at the Eye Level, A Randomized Controlled Trial. Presented
at the American Society of Cataract and Refractive Surgery (ASCRS)
Annual Meeting; May 5-8, 2023; San Diego, CA, USA.
- Zacharias J, Berthet N, Orellana D. Surge and Capsule Dynamics
during Phacoemulsification using an Adjustable Compliance
Mechanical Eye Mode. Presented at the American Society of Cataract
and Refractive Surgery (ASCRS) Annual Meeting; May 5-8, 2023; San
Diego, CA, USA.
- Scarfone HA, Rodriguez Emilia CC. Evaluation of Early Changes
of the Anterior Vitreous Interface After Cataract Surgery, Using
Low-Pressure Settings Determined By OCT. Presented at the American
Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting;
May 5-8, 2023; San Diego, CA, USA.
Disclaimer
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230501005394/en/
Investor Relations Allen
Trang + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
過去 株価チャート
から 4 2024 まで 5 2024
Alcon (NYSE:ALC)
過去 株価チャート
から 5 2023 まで 5 2024